ClotCare: Blood Clots, Stroke, Heart Attack
Saturday, June 24, 2017
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
information:
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

New Study Supports INR of 2 to 3 for Elderly Patients with A. Fib.

Henry I. Bussey, Pharm.D., FCCP, FAHA
November 2004

Review: Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004 Nov 16;141(10):745-52.

Elaine Hylek and her group from Boston have published several papers examining the benefit and safety of different levels of anticoagulation in selected patient populations. In this most recent paper by Fang, et al (including Dr. Hylek) (Ann Intern Med. 2004; 141:745-752) 170 cases of atrial fibrillation with intracranial hemorrhage were compared with 1,020 matched patients who did not have an intracranial hemorrhage. Key findings included that older age increased the risk of intracranial hemorrhage, but the increase was seen primarily when patients exceeded 85 years of age. An elevation in INR also was related to intracranial hemorrhage, but the increase was seen primarily when the INR was > 3.5. Finally, an INR of < 2 was not found to carry a lower risk of intracranial hemorrhage than an INR between 2 and 3. Consequently, there appears to be no benefit of treating elderly atrial fibrillation patients to an INR of less than 2 since it does not appear to be significantly safer and (as indicated in earlier studies by Hylek and colleagues) the risk of stroke doubles when the INR falls to 1.7 and triples when the INR is at 1.5.

Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org.

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

Research Company Seeks Patients who Have Had a Leg Blood Clot (deep vein thrombosis or DVT)

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2014 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-495-4335
Send comments to webmaster@clotcare.org.
Saturday, June 24, 2017